Literature DB >> 23386128

Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells.

Randall K Merling1, Colin L Sweeney, Uimook Choi, Suk See De Ravin, Timothy G Myers, Francisco Otaizo-Carrasquero, Jason Pan, Gilda Linton, Lifeng Chen, Sherry Koontz, Narda L Theobald, Harry L Malech.   

Abstract

A variety of somatic cells can be reprogrammed to induced pluripotent stem cells (iPSCs), but CD34(+) hematopoietic stem cells (HSCs) present in nonmobilized peripheral blood (PB) would be a convenient target. We report a method for deriving iPSC from PB HSCs using immunobead purification and 2- to 4-day culture to enrich CD34(+) HSCs to 80% ± 9%, followed by reprogramming with loxP-flanked polycistronic (human Oct4, Klf4, Sox2, and c-Myc) STEMCCA-loxP lentivector, or with Sendai vectors. Colonies arising with STEMCCA-loxP were invariably TRA-1-60(+), yielding 5.3 ± 2.8 iPSC colonies per 20 mL PB (n = 17), where most colonies had single-copy STEMCCA-loxP easily excised by transient Cre expression. Colonies arising with Sendai were variably reprogrammed (10%-80% TRA-1-60(+)), with variable yield (6 to >500 TRA-1-60(+) iPSC colonies per 10 mL blood; n = 6). Resultant iPSC clones expressed pluripotent cell markers and generated teratomas. Genomic methylation patterns of STEMCCA-loxP-reprogrammed clones closely matched embryonic stem cells. Furthermore, we showed that iPSCs are derived from the nonmobilized CD34(+) HSCs enriched from PB rather than from any lymphocyte or monocyte contaminants because they lack somatic rearrangements typical of T or B lymphocytes and because purified CD14(+) monocytes do not yield iPSC colonies under these reprogramming conditions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23386128      PMCID: PMC3617640          DOI: 10.1182/blood-2012-03-420273

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood.

Authors:  Hideki Hanawa; Patrick F Kelly; Amit C Nathwani; Derek A Persons; Jody A Vandergriff; Phillip Hargrove; Elio F Vanin; Arthur W Nienhuis
Journal:  Mol Ther       Date:  2002-03       Impact factor: 11.454

2.  An improved method for generating and identifying human induced pluripotent stem cells.

Authors:  Prashant Mali; Zhaohui Ye; Bin-Kuan Chou; Jonathan Yen; Linzhao Cheng
Journal:  Methods Mol Biol       Date:  2010

Review 3.  DNA repair defects in stem cell function and aging.

Authors:  Youngji Park; Stanton L Gerson
Journal:  Annu Rev Med       Date:  2005       Impact factor: 13.739

4.  Controlled expression of transgenes introduced by in vivo electroporation.

Authors:  Takahiko Matsuda; Constance L Cepko
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-05       Impact factor: 11.205

5.  Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells.

Authors:  Ori Bar-Nur; Holger A Russ; Shimon Efrat; Nissim Benvenisty
Journal:  Cell Stem Cell       Date:  2011-07-08       Impact factor: 24.633

6.  Granulocyte colony-stimulating factor recruitment of CD34+ progenitors to peripheral blood: impaired mobilization in chronic granulomatous disease and adenosine deaminase--deficient severe combined immunodeficiency disease patients.

Authors:  S Sekhsaria; T A Fleisher; S Vowells; M Brown; J Miller; I Gordon; R M Blaese; C E Dunbar; S Leitman; H L Malech
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

7.  Generation of induced pluripotent stem cells from human blood.

Authors:  Yuin-Han Loh; Suneet Agarwal; In-Hyun Park; Achia Urbach; Hongguang Huo; Garrett C Heffner; Kitai Kim; Justine D Miller; Kitwa Ng; George Q Daley
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

8.  Generation of human induced pluripotent stem cells from dermal fibroblasts.

Authors:  W E Lowry; L Richter; R Yachechko; A D Pyle; J Tchieu; R Sridharan; A T Clark; K Plath
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-15       Impact factor: 11.205

9.  Induced pluripotent stem cell lines derived from human somatic cells.

Authors:  Junying Yu; Maxim A Vodyanik; Kim Smuga-Otto; Jessica Antosiewicz-Bourget; Jennifer L Frane; Shulan Tian; Jeff Nie; Gudrun A Jonsdottir; Victor Ruotti; Ron Stewart; Igor I Slukvin; James A Thomson
Journal:  Science       Date:  2007-11-20       Impact factor: 47.728

10.  Induction of pluripotent stem cells from adult human fibroblasts by defined factors.

Authors:  Kazutoshi Takahashi; Koji Tanabe; Mari Ohnuki; Megumi Narita; Tomoko Ichisaka; Kiichiro Tomoda; Shinya Yamanaka
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

View more
  44 in total

1.  Reprogramming human B cells into induced pluripotent stem cells and its enhancement by C/EBPα.

Authors:  C Bueno; J L Sardina; B Di Stefano; D Romero-Moya; A Muñoz-López; L Ariza; M C Chillón; A Balanzategui; J Castaño; A Herreros; M F Fraga; A Fernández; I Granada; O Quintana-Bustamante; J C Segovia; K Nishimura; M Ohtaka; M Nakanishi; T Graf; P Menendez
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

2.  Targeted Repair of CYBB in X-CGD iPSCs Requires Retention of Intronic Sequences for Expression and Functional Correction.

Authors:  Colin L Sweeney; Jizhong Zou; Uimook Choi; Randall K Merling; Alexander Liu; Aaron Bodansky; Sandra Burkett; Jung-Woong Kim; Suk See De Ravin; Harry L Malech
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

Review 3.  Concise review: modeling central nervous system diseases using induced pluripotent stem cells.

Authors:  Xianmin Zeng; Joshua G Hunsberger; Anton Simeonov; Nasir Malik; Ying Pei; Mahendra Rao
Journal:  Stem Cells Transl Med       Date:  2014-11-03       Impact factor: 6.940

Review 4.  Methods of induced pluripotent stem cells for clinical application.

Authors:  Tomohisa Seki; Keiichi Fukuda
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

Review 5.  Inducing pluripotency in vitro: recent advances and highlights in induced pluripotent stem cells generation and pluripotency reprogramming.

Authors:  I K Rony; A Baten; J A Bloomfield; M E Islam; M M Billah; K D Islam
Journal:  Cell Prolif       Date:  2015-01-29       Impact factor: 6.831

6.  Efficient Generation of β-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells from Patients with Sickle Cell Disease.

Authors:  Naoya Uchida; Juan J Haro-Mora; Atsushi Fujita; Duck-Yeon Lee; Thomas Winkler; Matthew M Hsieh; John F Tisdale
Journal:  Stem Cells       Date:  2016-10-26       Impact factor: 6.277

7.  An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous disease.

Authors:  Randall K Merling; Colin L Sweeney; Jessica Chu; Aaron Bodansky; Uimook Choi; Debra Long Priel; Douglas B Kuhns; Hongmei Wang; Sam Vasilevsky; Suk See De Ravin; Thomas Winkler; Cynthia E Dunbar; Jizhong Zou; Kol A Zarember; John I Gallin; Steven M Holland; Harry L Malech
Journal:  Mol Ther       Date:  2014-10-07       Impact factor: 11.454

8.  CRISPR/Cas9-Based Safe-Harbor Gene Editing in Rhesus iPSCs.

Authors:  Ravi Chandra Yada; John W Ostrominski; Ilker Tunc; So Gun Hong; Jizhong Zou; Cynthia E Dunbar
Journal:  Curr Protoc Stem Cell Biol       Date:  2017-11-15

9.  Rhesus Macaque iPSC Generation and Maintenance.

Authors:  Ravi Chandra Yada; So Gun Hong; Yongshun Lin; Thomas Winkler; Cynthia E Dunbar
Journal:  Curr Protoc Stem Cell Biol       Date:  2017-05-16

10.  Induced pluripotent stem cell reprogramming by integration-free Sendai virus vectors from peripheral blood of patients with craniometaphyseal dysplasia.

Authors:  I-Ping Chen; Keiichi Fukuda; Noemi Fusaki; Akihiro Iida; Mamoru Hasegawa; Alexander Lichtler; Ernst J Reichenberger
Journal:  Cell Reprogram       Date:  2013-11-12       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.